Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback